Targeting phospholipase A2 for the treatment of inflammatory skin diseases.
Due to the problems associated with current treatments for inflammatory disorders of the skin, the pharmaceutical industry has focused on novel ways to treat these disorders. Lipid-derived eicosanoids, which play an important role in the underlying inflammation in psoriasis and atopic dermatitis, can be derived from the phospholipase (PLA)-dependent production of arachidonate. In this review, the characteristics and promise of PLA, inhibitors, which have shown activity in preclinical models of skin inflammation are discussed along with the challenges the field faces in developing clinical candidates.
Burke
J R
JR
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA. james.burke@bms.com
D000818:Animals; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000201:enzymology; D016503:Drug Delivery Systems / Q000379:methods*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D054467:Phospholipases A2; D011565:Psoriasis / Q000188:drug therapy* / Q000201:enzymology
D004791:Enzyme Inhibitors; D010741:Phospholipases A; D054467:Phospholipases A2